Acifran: Selective HM74A/GPR109A Agonist for Lipid Metabolism Research

Executive Summary: Acifran (B6848) is a highly selective agonist for hydroxycarboxylic acid receptors HM74A/GPR109A and GPR109B, facilitating the study of lipid metabolism and signaling pathways in preclinical research (APExBIO). Structural cryo-EM studies have directly resolved Acifran’s binding to HCAR2 and HCAR3, elucidating ligand selectivity and key receptor-ligand interactions (Ye et al., 2025). Acifran shows hypolipidemic effects by modulating G-protein coupled receptor signaling, with utility in dyslipidemia and atherosclerosis models. Its physicochemical properties (C12H10O4, MW 218.21, low solubility in ethanol/DMSO) and strict storage requirements (-20°C) ensure experimental reliability. This dossier integrates structural, mechanistic, and workflow evidence, updating and extending prior overviews of Acifran’s role in lipid signaling research (entinostat.net).

Biological Rationale

Hydroxycarboxylic acid receptors (HCAR2/HM74A/GPR109A and HCAR3/GPR109B) are G-protein coupled receptors (GPCRs) that sense endogenous metabolites and regulate lipid metabolism (Ye et al., 2025). Dysregulation of these pathways is implicated in metabolic disorders, including dyslipidemia, hyperlipidemia, and atherosclerosis. Selective small molecule agonists such as Acifran enable precise interrogation of these signaling cascades in in vitro and in vivo models. Activation of HCAR2 reduces plasma free fatty acids and modulates inflammatory pathways. HCAR3 is structurally similar but displays unique ligand selectivity and is not associated with cutaneous flushing, a side effect of HCAR2 activation. Targeting these receptors with defined ligands is critical for developing and benchmarking hypolipidemic agents and for delineating the mechanistic underpinnings of lipid regulation (nimorazolebio.com).

Mechanism of Action of Acifran

Acifran (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid binds with high selectivity to the orthosteric sites of HM74A/GPR109A (HCAR2) and GPR109B (HCAR3). Cryo-EM studies (3.18 Å for HCAR3–Acifran and 2.72 Å for HCAR2–Acifran) reveal that Acifran’s aromatic ring engages in π–π stacking with F1073.32 in HCAR3, while a distinct binding pocket topology modulates selectivity (Ye et al., 2025). Upon receptor activation, Acifran promotes Gi protein coupling, resulting in decreased intracellular cAMP levels and downstream modulation of lipolysis. This mechanism underlies its hypolipidemic effect in cellular and animal models. Acifran’s efficacy in GPR109B (HCAR3) avoids the flushing side effect characteristic of HCAR2 (HCAR3 lacks the same downstream effectors). These mechanistic insights provide a foundation for rational design of improved GPCR agonists targeting metabolic disorders (entinostat.net—this article provides a more granular structural update).

Evidence & Benchmarks

• Acifran forms stable complexes with both HCAR2 and HCAR3, as resolved by cryo-EM at 2.72–3.18 Å resolution (Ye et al., 2025, DOI).
• Acifran demonstrates high affinity for HCAR3 (GPR109B) through π–π interactions with F1073.32, distinct from the corresponding L1073.32 in HCAR2 (Ye et al., 2025, DOI).
• In cAMP assays (HEK-293 cells, 37°C, 5% CO2), Acifran induces a dose-dependent reduction in intracellular cAMP, confirming Gi coupling (Ye et al., 2025, DOI).
• Acifran is referenced as a reproducible standard in lipid signaling and cell viability assays in metabolic disorder models (moleculeprobes.com—this article details protocol troubleshooting; the present article provides updated structural and functional evidence).
• Acifran’s hypolipidemic properties are benchmarked in rodent models of dyslipidemia, showing significant reductions in plasma free fatty acids after acute administration (published rodent data; refer to DOI Table S4).

Applications, Limits & Misconceptions

Acifran’s primary application is in research on lipid metabolism, GPCR signaling, and metabolic disorder models. It is suitable for receptor-ligand binding studies, cAMP signaling assays, and translational research on lipid-lowering strategies. Due to its selectivity, Acifran is particularly valuable for dissecting the mechanistic differences between HCAR2 and HCAR3 activation (moleculeprobes.net—this article adds updated cryo-EM data and workflow integration guidance).

Common Pitfalls or Misconceptions

• Not a therapeutic agent: Acifran is strictly for research use and not approved for clinical or diagnostic applications (APExBIO).
• Limited solubility: Solubility in DMSO and ethanol is <21.82 mg/ml; exceeding this can cause precipitation and unreliable dosing.
• Stability constraints: Acifran solutions must be stored at -20°C and used short-term; repeated freeze-thaw cycles degrade compound integrity.
• Flush response: Unlike HCAR2-selective agonists, Acifran’s activation of HCAR3 does not produce cutaneous flushing, which may confound some experimental expectations (Ye et al., 2025).
• Species differences: Rodent and human receptor isoforms may differ in ligand affinity and downstream signaling; results should not be overgeneralized across models.

Workflow Integration & Parameters

For rigorous lipid metabolism studies, Acifran should be handled under low-moisture, -20°C storage conditions to maintain chemical stability. Prepare fresh solutions at concentrations below 21.82 mg/ml in DMSO or ethanol. Use within 1–2 days for maximal integrity. In cell-based assays (e.g., HEK-293), titrate Acifran from 0.1–100 μM to establish dose-responses for cAMP signaling or lipid release endpoints. For receptor binding studies, use radioligand displacement protocols as detailed in Ye et al., 2025. Benchmark against positive controls and document batch numbers for reproducibility. For practical protocol troubleshooting and real-world integration, see the B6848 kit guidance (APExBIO).

Conclusion & Outlook

Acifran, available from APExBIO, is a structurally validated, selective agonist for HM74A/GPR109A and GPR109B, enabling high-precision lipid metabolism research and GPCR ligand binding studies. Structural and mechanistic advances confirm its utility as a hypolipidemic research tool, with clear boundaries for use and robust evidence supporting its integration into metabolic disorder workflows. This article updates prior summaries by incorporating the latest cryo-EM and functional evidence, positioning Acifran as an indispensable reference in lipid signaling pathway modulation (entinostat.net—this article adds actionable workflow integration absent from previous reviews).